These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 17448109)
41. A struggle to SURVIVE: to abandon or not to abandon levosimendan? Butler J; Giamouzis G; Giannakoulas G Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453 [No Abstract] [Full Text] [Related]
42. Can we believe in levosimendan? Follath F Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391 [No Abstract] [Full Text] [Related]
44. Is there a place for levosimendan in the intensive care unit? Simes DC Crit Care Resusc; 2007 Dec; 9(4):395. PubMed ID: 18052906 [No Abstract] [Full Text] [Related]
45. Levosimendan and quality of life. Papadopoulos CE; Zioutas DG; Dalamaga EG Hellenic J Cardiol; 2010; 51(1):81-2. PubMed ID: 20118051 [No Abstract] [Full Text] [Related]
46. [Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report]. Biegus J; Zymliński R; Kulej K; Szachniewicz J; Banasiak W; Jankowska EA; Ponikowski P Kardiol Pol; 2013; 71(3):275-8. PubMed ID: 23575784 [TBL] [Abstract][Full Text] [Related]
47. Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence? Wikström BG Eur J Heart Fail; 2010 Aug; 12(8):893. PubMed ID: 20675671 [No Abstract] [Full Text] [Related]
48. Clinical significance of acute neurohormonal response after levosimendan treatment. Giannakoulas G; Giannoglou G; Vassilikos V; Martiadou K; Kalpidis P; Parharidis G; Louridas G Am J Cardiol; 2006 Oct; 98(8):1123-4. PubMed ID: 17027590 [No Abstract] [Full Text] [Related]
49. Resuscitation from adrenaline resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy. Tsagalou EP; Nanas JN Resuscitation; 2006 Jan; 68(1):147-9. PubMed ID: 16325323 [TBL] [Abstract][Full Text] [Related]
50. [Inotropic agents in advanced and refractory heart failure]. Mangiavacchi M; Gronda E Ital Heart J Suppl; 2003 Jan; 4(1):3-7. PubMed ID: 12690928 [No Abstract] [Full Text] [Related]
55. The case for levosimendan. De Keulenaer BL Crit Care Resusc; 2008 Sep; 10(3):180. PubMed ID: 18798714 [No Abstract] [Full Text] [Related]
56. Levosimendan use in several scenarios of acute heart failure. Tavares M; Andrade AC; Mebazaa A Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402 [TBL] [Abstract][Full Text] [Related]
57. [Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis]. Xu ZD; He WX; Zhao YF; Xia SX; He B; Yang T; Cao DX; Peng SL; Li J; Cao MH Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2027-9. PubMed ID: 19861257 [TBL] [Abstract][Full Text] [Related]
58. Inotropes in the management of acute heart failure. Petersen JW; Felker GM Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469 [TBL] [Abstract][Full Text] [Related]
59. Cardioprotection: a new paradigm in the management of acute heart failure syndromes. Maytin M; Colucci WS Am J Cardiol; 2005 Sep; 96(6A):26G-31G. PubMed ID: 16181820 [TBL] [Abstract][Full Text] [Related]